Skip to main content
. Author manuscript; available in PMC: 2009 Sep 2.
Published in final edited form as: Cancer Res. 2008 Sep 1;68(17):6953–6962. doi: 10.1158/0008-5472.CAN-08-0365

Figure 5.

Figure 5

BAP1-mediated suppression of NCI-H226 cell tumorigenicity in vivo requires deubiquitinating activity and nuclear localization. Athymic nu/nu female mice (5–6 weeks old) were injected subcutaneously with 1×106 NCI-H226 cells carrying vector alone (VC), or vector encoding wild-type BAP1 (WT), active-site point mutant BAP1 (C91A), or mutant BAP1 that does not localize to the nucleus (NLS2-Ala). (A) Tumor growth rates represented as mm3/day ± SD. (B) The mean tumor volume was plotted as a function of time using the formula (Length x width2 x ½). P-values shown are compared to WT BAP1 tumors. Other p-values are as follows: VC vs. C19A=0.1143; VC vs. NLS2-Ala=0.1206; C91A vs. NLS2-Ala=0.6844. n = 8. (C) Representative tumors excised from mice. Numbers at top represent mouse number.